BRAF and colorectal carcinoma: In addition, the TF-IDF value of BRAF mutation in colorectal cancers increased because of the better outcomes of the BRAF-mutant CRC tumors with microsatellite instability (MSI) in immunotherapy (Rosenbaum et al., 2016).